Review · United States
Ipamorelin
Reviewed on
Approval and product status
Still being studied; no FDA-approved product identified
Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.
What was measured in people?
- Health results · Limited
- A phase 2 trial did not show significant benefit on its key efficacy endpoint.
- Body changes · Moderate
- Dose-escalation work characterizes short-lived GH release in healthy volunteers.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.
Still unknown: Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.
Read all Ipamorelin fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 4 sources
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
PubMed · Pharmaceutical Research · Human pharmacology · 1999
Source accessed
- Randomized proof-of-concept study of ipamorelin for postoperative ileus
PubMed · International Journal of Colorectal Disease · Randomized trial · 2015
Source accessed
- Certain bulk drug substances that may present significant safety risks
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- 2026 prohibited list
World Anti-Doping Agency · Anti-doping · 2026
Source accessed